Citadel Advisors LLC Makes New Investment in Odyssey Therapeutics, Inc. $ODTX

Citadel Advisors LLC purchased a new position in Odyssey Therapeutics, Inc. (NASDAQ:ODTX) in the second quarter, HoldingsChannel reports. The firm purchased 222,450 shares of the company’s stock, valued at approximately $4,162,000.

Analysts Set New Price Targets

A number of brokerages have issued reports on ODTX. Weiss Ratings initiated coverage on Odyssey Therapeutics in a research note on Tuesday, August 11th. They issued a “sell (d+)” rating for the company. Zacks Research upgraded Odyssey Therapeutics to a “hold” rating in a research report on Wednesday, June 3rd. Wedbush began coverage on Odyssey Therapeutics in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $30.00 target price for the company. Wall Street Zen downgraded Odyssey Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 20th. Finally, TD Cowen started coverage on shares of Odyssey Therapeutics in a report on Tuesday, June 2nd. They set a “buy” rating for the company. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $35.75.

Odyssey Therapeutics Price Performance

NASDAQ ODTX opened at $28.76 on Tuesday. The stock has a market cap of $1.38 billion and a PE ratio of -4.25. The company’s 50 day moving average price is $20.66. Odyssey Therapeutics, Inc. has a 1-year low of $15.10 and a 1-year high of $29.05.

Odyssey Therapeutics (NASDAQ:ODTX) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.74) earnings per share (EPS) for the quarter. Equities analysts predict that Odyssey Therapeutics, Inc. will post -5.99 EPS for the current fiscal year.

About Odyssey Therapeutics

Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines which are designed to precisely target disease pathology. Odyssey Therapeutics Inc is based in BOSTON.